Impax Laboratories Appoints New Board Member
This article was originally published in Scrip
Impax Laboratories has appointed Janet S. Vergis to its board of directors – effective Oct.7, 2015. Since 2013, Vergis has been executive advisor for private equity firms and is currently at Water Street Healthcare Partners, LLC. and Deerfield Management. Previously she was an executive in residence advisor at Warburg Pincus, LLC. Prior to her advisory roles, Vergis was CEO of OraPharma, Inc. and before that she held various executive leadership roles at Johnson & Johnson and its subsidiaries, including Janssen Pharmaceuticals, McNeil Pediatrics and Ortho-McNeil Neurologics, where she was president.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.